FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rüdiger Hehlmann

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Living Beings

Retroviridae

Co-author Network

Publications

TOP 3
Richard A Van Etten; Carlo Gambacorti-Passerini; John M Goldman; Rüdiger Hehlmann; Catriona Jamieson; Giovanni Martinelli; Michael Mauro; Danilo Perrotti; Jerald P Radich; Giuseppe Saglio; David T Scadden; Tomasz Skorski; Simona Soverini; Ayalew Tefferi; Tariq I Mughal
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
Matthias Horn; Markus Loeffler; Martin C Müller; Ingmar Glauche; Rüdiger Hehlmann; Andreas Hochhaus; Ingo Roeder
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Eva Lengfelder; Carsten Müller-Tidow; Cristina Sauerland; Stephanie Schneider; Susanne Schnittger; Beate Schultheis; Hubert Serve; Karsten Spiekermann; Bernhard Wörmann; Carlo Aul; Wolfgang E Berdel; Jan Braess; Thomas Büchner; Philipp Erben; Claudia Haferlach; Torsten Haferlach; Benjamin Hanfstein; Rüdiger Hehlmann; Achim Heinecke; Wolfgang Hiddemann; Wolf-Karsten Hofmann; Heinz A Horst; Karl-Anton Kreuzer; Utz Krug
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rüdiger Hehlmann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Richard A Van Etten; Carlo Gambacorti-Passerini; John M Goldman; Rüdiger Hehlmann; Catriona Jamieson; Giovanni Martinelli; Michael Mauro; Danilo Perrotti; Jerald P Radich; Giuseppe Saglio; David T Scadden; Tomasz Skorski; Simona Soverini; Ayalew Tefferi; Tariq I Mughal
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
Leukemia & lymphoma 2013;54(6):1151-8.
2013: Matthias Horn; Markus Loeffler; Martin C Müller; Ingmar Glauche; Rüdiger Hehlmann; Andreas Hochhaus; Ingo Roeder
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Blood 2013;121(2):378-84.
2013: Eva Lengfelder; Carsten Müller-Tidow; Cristina Sauerland; Stephanie Schneider; Susanne Schnittger; Beate Schultheis; Hubert Serve; Karsten Spiekermann; Bernhard Wörmann; Carlo Aul; Wolfgang E Berdel; Jan Braess; Thomas Büchner; Philipp Erben; Claudia Haferlach; Torsten Haferlach; Benjamin Hanfstein; Rüdiger Hehlmann; Achim Heinecke; Wolfgang Hiddemann; Wolf-Karsten Hofmann; Heinz A Horst; Karl-Anton Kreuzer; Utz Krug
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Annals of hematology 2013;92(1):41-52.
2012: Thomas Büchner; Hartmut Döhner; Konstanze Döhner; Gerhard Ehninger; Arnold Ganser; Joerg Hasford; Rüdiger Hehlmann; Gerhard Heil; Achim Heinecke; Wolfgang Hiddemann; Dieter Hoelzer; Verena S Hoffmann; Rainer Krahl; Michael Kramer; Jürgen Krauter; Utz Krug; Dietger W Niederwieser; Maria Cristina Sauerland; Markus Schaich; Richard F Schlenk; Sebastian Scholl; Daniela Späth; Wolfgang E Berdel; Markus Pfirrmann
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(29):3604-10.
2012: Rüdiger Hehlmann
How I treat CML blast crisis.
Blood 2012;120(4):737-47.
2012: Joëlle Guilhot; Michele Baccarani; Francisco Cervantes; Richard E Clark; François Guilhot; Andreas Hochhaus; Sergei Kulikov; Jiri Mayer; Andreas L Petzer; Gianantonio Rosti; Philippe Rousselot; Giuseppe Saglio; Susanne Saussele; Bengt Simonsson; Juan-Luis Steegmann; Andrey Zaritskey; Rüdiger Hehlmann
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Blood 2012;119(25):5963-71.
2012: Verena Hoffmann; Doris Lindoerfer; Gert Ossenkoppele; Markus Pfirrmann; Kimmo Porkka; Gianantonio Rosti; Susanne Saussele; Bengt Simonsson; Michele Baccarani; François Guilhot; Joelle Guilhot; Joerg Hasford; Rüdiger Hehlmann
The EUTOS CML score aims to support clinical decision-making.
Blood 2012;119(12):2966-7.
2011: Markus Pfirrmann; Susanne Saussele; Rüdiger Hehlmann; Andreas Hochhaus; M Lauseker; Joerg Hasford
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.
Leukemia 2011;25(9):1433-8.
2011: Rüdiger Hehlmann; Andreas Hochhaus; Dieter K Hossfeld; Susanne Jung-Munkwitz; Stefan W Krause; Michael Lauseker; Armin Leitner; Martin C Müller; Christoph Nerl; Markus Pfirrmann; Nadine Pletsch; Hans Pralle; Ulrike Proetel; Leopold Balleisen; Alois Gratwohl; Claudia Haferlach; Mathias Hänel; Joerg Hasford; Brigitte Schlegelberger; Susanne Saussele
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(12):1634-42.
2011: Benjamin Hanfstein; Martin C Müller; Sebastian Kreil; Thomas Ernst; Thomas Schenk; Christian Lorentz; Uwe Schwindel; Armin Leitner; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Haematologica 2011;96(3):360-6.
2011: Rüdiger Hehlmann; Susanne Jung-Munkwitz; Susanne Saussele
Treatment of chronic myeloid leukemia when imatinib fails.
Expert opinion on pharmacotherapy 2011;12(2):269-83.
2010: Susanne Saussele; Michael Lauseker; Alois Gratwohl; Dietrich W Beelen; Donald Bunjes; Rainer Schwerdtfeger; Hans-Jochem Kolb; Anthony D Ho; Christiane Falge; Ernst Holler; Günter Schlimok; Axel R Zander; Renate Arnold; Lothar Kanz; Robert Dengler; Claudia Haferlach; Brigitte Schlegelberger; Markus Pfirrmann; Martin C Müller; Susanne Schnittger; Armin Leitner; Nadine Pletsch; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Blood 2010;115(10):1880-5.
2010: Andreas Burchert; Martin C Müller; Philippe Kostrewa; Philipp Erben; Tilman Bostel; Simone Liebler; Rüdiger Hehlmann; Andreas Neubauer; Andreas Hochhaus
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(8):1429-35.
2010: Sebastian Kreil; Katherine Waghorn; Thomas Ernst; Andrew Chase; Helen White; Rüdiger Hehlmann; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross
A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α.
Haematologica 2010;95(1):148-52.
2009: Eva Lengfelder; Claudia Haferlach; Susanne Saussele; Torsten Haferlach; Beate Schultheis; S Schnittger; Wolf-Dieter Ludwig; Peter Staib; Carlo Aul; A Grüneisen; W Kern; A Reichle; Hubert Serve; Wolfgang E Berdel; J Braess; K Spiekermann; Bernhard Wörmann; Maria Cristina Sauerland; Achim Heinecke; Wolfgang Hiddemann; Rüdiger Hehlmann; Thomas Büchner
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.
Leukemia 2009;23(12):2248-58.
2009: Georgia Metzgeroth; Dietmar Dinter; Beate Schultheis; Alexandra Dorn-Beineke; Kira Lutz; Oliver Leismann; Rüdiger Hehlmann; Jan Hastka
Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Annals of hematology 2009;88(4):301-10.
2008: Georgia Metzgeroth; Christoph Walz; Philipp Erben; Helena Popp; Annette Schmitt-Graeff; Claudia Haferlach; Alice Fabarius; Susanne Schnittger; David Grimwade; Nicholas C P Cross; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Reiter
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
British journal of haematology 2008;143(5):707-15.
2008: Thomas Ernst; Jana Hoffmann; Philipp Erben; Benjamin Hanfstein; Armin Leitner; Rüdiger Hehlmann; Andreas Hochhaus; Martin C Müller
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Haematologica 2008;93(9):1389-93.
2008: Alice Fabarius; Michelle Giehl; Blanka Rebacz; Alwin Krämer; Oliver Frank; Claudia Haferlach; Peter Duesberg; Rüdiger Hehlmann; Wolfgang Seifarth; Andreas Hochhaus
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib.
Haematologica 2008;93(8):1145-54.
2008: Georgia Metzgeroth; Christian Kuhn; Beate Schultheis; Rüdiger Hehlmann; Jan Hastka
Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions.
Cytopathology : official journal of the British Society for Clinical Cytology 2008;19(4):205-11.
2008: Paul La Rosée; Susanne Holm-Eriksen; Heiko Konig; Nicolai Härtel; Thomas Ernst; Julia Debatin; Martin C Mueller; Philipp Erben; Anja Binckebanck; Lydia Wunderle; Yaping Shou; Margaret Dugan; Rüdiger Hehlmann; Oliver G Ottmann; Andreas Hochhaus
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Haematologica 2008;93(5):765-9.
2008: Margit Hummel; Sebastian Reiter; Katja Adam; Rüdiger Hehlmann; Dieter Buchheidt
Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
European journal of haematology 2008;80(4):331-6.
2008: Margit Hummel; Silke Rudert; Herbert Hof; Rüdiger Hehlmann; Dieter Buchheidt
Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates.
Annals of hematology 2008;87(4):291-7.
2008: Thomas Ernst; Philipp Erben; Martin C Müller; Peter Paschka; Thomas Schenk; Jana Hoffmann; Sebastian Kreil; Paul La Rosée; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Haematologica 2008;93(2):186-92.
2008: Oliver Frank; Caroline Verbeke; Norbert Schwarz; Jens Mayer; Alice Fabarius; Rüdiger Hehlmann; Christine Leib-Mösch; Wolfgang Seifarth
Variable transcriptional activity of endogenous retroviruses in human breast cancer.
Journal of virology 2008;82(4):1808-18.
2008: Alice Fabarius; Ruhong Li; George Yerganian; Rüdiger Hehlmann; Peter Duesberg
Specific clones of spontaneously evolving karyotypes generate individuality of cancers.
Cancer genetics and cytogenetics 2008;180(2):89-99.
2008: Alice Fabarius; Peter Duesberg; Michelle Giehl; Wolfgang Seifarth; Andreas Hochhaus; Rüdiger Hehlmann
Genomic instability in context of the chromosomal theory.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2008;30(6):503-4.
2008: Thomas Ernst; Jana Hoffmann; Philipp Erben; Rüdiger Hehlmann; Andreas Hochhaus; Martin C Müller
Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(3):318-22.
2008: Martin C Müller; Philipp Erben; Giuseppe Saglio; Enrico Gottardi; C G Nyvold; T Schenk; T Ernst; S Lauber; J Kruth; Rüdiger Hehlmann; Andreas Hochhaus
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.
Leukemia 2008;22(1):96-102.
2007: Birgit Spiess; Wolfgang Seifarth; Margit Hummel; Oliver Frank; Alice Fabarius; Chun Zheng; Handan Mörz; Rüdiger Hehlmann; Dieter Buchheidt
DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients.
Journal of clinical microbiology 2007;45(11):3743-53.
2007: Michelle Giehl; Alice Fabarius; Oliver Frank; Philipp Erben; Chun Zheng; M Hafner; Andreas Hochhaus; Rüdiger Hehlmann; Wolfgang Seifarth
Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.
Leukemia 2007;21(9):1971-6.
2007: Sebastian Kreil; Markus Pfirrmann; Claudia Haferlach; Katherine Waghorn; Andrew Chase; Rüdiger Hehlmann; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.
Blood 2007;110(4):1283-90.
2007: Alice Fabarius; Michelle Giehl; Oliver Frank; Birgit Spiess; Chun Zheng; Martin C Müller; Christel Weiss; Peter Duesberg; Rüdiger Hehlmann; Andreas Hochhaus; Wolfgang Seifarth
Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability.
British journal of haematology 2007;138(3):369-73.
2007: Rüdiger Hehlmann; Andreas Hochhaus; Michele Baccarani
Chronic myeloid leukaemia.
Lancet 2007;370(9584):342-50.
2007: Martin C Müller; Guiseppe Saglio; Feng Lin; Heike Pfeifer; Richard D Press; Raymond R Tubbs; Peter Paschka; Enrico Gottardi; Steven G O'Brien; Oliver G Ottmann; Hubertus Stockinger; Lothar Wieczorek; Kirsten Merx; Heiko König; Uwe Schwindel; Rüdiger Hehlmann; Andreas Hochhaus
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.
Haematologica 2007;92(7):970-3.
2007: Georgia Metzgeroth; Paul La Rosée; Christian Kuhn; Beate Schultheis; Alexandra Dorn-Beineke; Rüdiger Hehlmann; Jan Hastka
The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome.
European journal of haematology 2007;79(1):8-16.
2007: Georgia Metzgeroth; Carola Mantz; Christian Kuhn; Beate Schultheis; Rüdiger Hehlmann; Jan Hastka
Reliable identification of small cell lung cancer in cytological specimens by immunocytology.
Onkologie 2007;30(6):311-5.
2007: Heiko Konig; Nicolai Härtel; Beate Schultheis; Michael Schatz; Christian Lorentz; Junia V Melo; Rüdiger Hehlmann; Andreas Hochhaus; Paul La Rosée
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Haematologica 2007;92(6):838-41.
2007: Alice Fabarius; Claudia Haferlach; Martin C Müller; Philipp Erben; Tanja Lahaye; Michelle Giehl; Oliver Frank; Wolfgang Seifarth; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Haematologica 2007;92(6):834-7.
2007: Georgia Metzgeroth; Christoph Walz; Joannah Score; R Siebert; S Schnittger; Claudia Haferlach; H Popp; Torsten Haferlach; Philipp Erben; J Mix; Martin C Müller; H Beneke; L Müller; F Del Valle; Walter Aulitzky; G Wittkowsky; Norbert Schmitz; C Schulte; K Müller-Hermelink; E Hodges; S J Whittaker; F Diecker; H Döhner; P Schuld; Rüdiger Hehlmann; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Leukemia 2007;21(6):1183-8.
2007: Rüdiger Hehlmann; Ute Berger; Markus Pfirrmann; Hermann Heimpel; Andreas Hochhaus; Joerg Hasford; Hans-Jochem Kolb; Tanja Lahaye; Ole Maywald; Andreas Reiter; Dieter K Hossfeld; Christoph Huber; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Tobler; Christoph Nerl; Max Solenthaler; Mariele E Goebeler; Martin Griesshammer; Thomas Fischer; Stephan Kremers; Hartmut Eimermacher; Michael Pfreundschuh; Wolf-Dietrich Hirschmann; Klaus Lechner; Barbara Wassmann; Christiane Falge; Hartmut H Kirchner; Alois Gratwohl
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
Blood 2007;109(11):4686-92.
2007: Jelena V Jovanovic; Joannah Score; Katherine Waghorn; Daniela Cilloni; Enrico Gottardi; Georgia Metzgeroth; Philipp Erben; Helena Popp; Christoph Walz; Andreas Hochhaus; Catherine Roche-Lestienne; Claude Preudhomme; Ellen Solomon; Jane Apperley; Michela Rondoni; Emanuela Ottaviani; giovanni martinelli; Finella Brito-Babapulle; Giuseppe Saglio; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter; David Grimwade
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Blood 2007;109(11):4635-40.
2007: Georgia Metzgeroth; Beate Schultheis; Alexandra Dorn-Beineke; Rüdiger Hehlmann; Jan Hastka
Zinc protoporphyrin, a useful parameter to address hyperferritinemia.
Annals of hematology 2007;86(5):363-8.
2007: Stefan Fruehauf; Julian Topaly; Eike C Buss; Thomas Fischer; Oliver G Ottmann; Bertold Emmerich; Martin C Müller; Peter Schuld; Leopold Balleisen; Rüdiger Hehlmann; Anthony Ho; Andreas Hochhaus
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Cancer 2007;109(8):1543-9.
2007: Eva Lengfelder; Beate Schultheis; T Büchner; Rüdiger Hehlmann
[Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Deutsche medizinische Wochenschrift (1946) 2007;132(7):330-6.
2007: Peter Duesberg; Ruhong Li; Rainer K Sachs; Alice Fabarius; Madhvi B Upender; Rüdiger Hehlmann
Cancer drug resistance: the central role of the karyotype.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2007;10(1-2):51-8.
2007: Christoph Walz; Georgia Metzgeroth; Claudia Haferlach; Annette Schmitt-Graeff; Alice Fabarius; Volker Hagen; Otto Prümmer; Stefan Rauh; Rüdiger Hehlmann; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Haematologica 2007;92(2):163-9.
2007: Georgia Metzgeroth; W Back; Beate Schultheis; Ole Maywald; C Kuhn; Rüdiger Hehlmann; Jan Hastka
Intestinal-type adenocarcinoma situated in the nasopharynx.
Cytopathology : official journal of the British Society for Clinical Cytology 2007;18(1):59-63.
2007: Georgia Metzgeroth; Beate Schultheis; Christian Kuhn; Alexandra Dorn-Beineke; Paul LaRosée; Rüdiger Hehlmann; Jan Hastka
The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2007;45(10):1313-8.
2007: Georgia Metzgeroth; Dietmar Dinter; Philipp Erben; Paul La Rosée; Rüdiger Hehlmann; Jan Hastka
Systemic mastocytosis simulating osseous metastatic disease.
British journal of haematology 2007;136(1):1.
2006: Margit Hummel; Birgit Spiess; K Kentouche; S Niggemann; C Böhm; S Reuter; M Kiehl; Handan Mörz; Rüdiger Hehlmann; Dieter Buchheidt
Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay.
Journal of clinical microbiology 2006;44(11):3989-93.
2006: Susanne Saussele; K Adam; Andreas Hochhaus; marie bene; Thomas Büchner; A Burnett; G Finazzi; Christa Fonatsch; E Gluckman; Nicola Gökbuget; David Grimwade; Torsten Haferlach; M Hallek; Joerg Hasford; Dieter Hoelzer; P Ljungman; Dietger Niederwieser; Hubert Serve; B Simonsson; T J de Witte; Rüdiger Hehlmann
[Clinical research at the European LeukemiaNet].
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2423-6.
2006: Silke Ulm; Margit Hummel; Michael Emig; Manuel Barreto-Miranda; Walter Back; Andreas Reiter; Rüdiger Hehlmann; Andreas Willer
Leukocytoclastic vasculitis and acute renal failure after influenza vaccination in an elderly patient with myelodysplastic syndrome.
Onkologie 2006;29(10):470-2.
2006: Christoph Walz; Claire Curtis; Susanne Schnittger; Beate Schultheis; Georgia Metzgeroth; Claudia Schoch; Eva Lengfelder; Philipp Erben; Martin C Müller; Torsten Haferlach; Andreas Hochhaus; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Genes, chromosomes & cancer 2006;45(10):950-6.
2006: Michele Baccarani; Giuseppe Saglio; John Goldman; Andreas Hochhaus; Bengt Simonsson; Frederick Appelbaum; Jane Apperley; Francisco Cervantes; Jorge Cortes; Michael W N Deininger; Alois Gratwohl; françois guilhot; Mary Horowitz; Timothy Hughes; Andrew Lamb; Richard Larson; Dietger Niederwieser; Richard Silver; Rüdiger Hehlmann
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Blood 2006;108(6):1809-20.
2006: Oliver Frank; B Brors; Alice Fabarius; L Li; Markus Haak; Sylvia Merk; Uwe Schwindel; Chun Zheng; Martin C Müller; Norbert Gretz; Rüdiger Hehlmann; Andreas Hochhaus; Wolfgang Seifarth
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.
Leukemia 2006;20(8):1400-7.
2006: Timothy Hughes; Michael W N Deininger; Andreas Hochhaus; Susan Branford; Jerald P Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; giovanni martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Blood 2006;108(1):28-37.
2006: Chun Zheng; L Li; Markus Haak; B Brors; Oliver Frank; Michelle Giehl; Alice Fabarius; M Schatz; Andreas Weisser; C Lorentz; Norbert Gretz; Rüdiger Hehlmann; Andreas Hochhaus; Wolfgang Seifarth
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.
Leukemia 2006;20(6):1028-34.
2006: Susanne Saussele; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Nicola Gökbuget; Dieter Hoelzer; Karl Uberla; Rüdiger Hehlmann
[Clinical research within the German competence net "acute and chronic leukemias"].
Medizinische Klinik (Munich, Germany : 1983) 2006;101(5):414-20.
2006: Eva Lengfelder; Kirsten Merx; Rüdiger Hehlmann
Diagnosis and therapy of polycythemia vera.
Seminars in thrombosis and hemostasis 2006;32(3):267-75.
2006: Ole Maywald; Markus Pfirrmann; Ute Berger; Lusine Breitscheidel; Alois Gratwohl; Hans-Jochem Kolb; D W Beelen; Andreas Tobler; Georgia Metzgeroth; S U Gnad; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann; Andreas Reiter
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.
Leukemia 2006;20(3):477-84.
2006: Peter Duesberg; Ruhong Li; Alice Fabarius; Rüdiger Hehlmann
Aneuploidy and cancer: from correlation to causation.
Contributions to microbiology 2006;13():16-44.
2005: Margit Hummel; Dieter Buchheidt; Sebastian Reiter; Jörg Bergmann; Katja Adam; Rüdiger Hehlmann
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
European journal of haematology 2005;75(6):518-21.
2005: Eva Lengfelder; Susanne Saussele; Andreas Weisser; Thomas Büchner; Rüdiger Hehlmann
Treatment concepts of acute promyelocytic leukemia.
Critical reviews in oncology/hematology 2005;56(2):261-74.
2005: Georgia Metzgeroth; Verena Adelberger; Alexandra Dorn-Beineke; Christian Kuhn; Michael Schatz; Ole Maywald; Thomas Bertsch; Hermann Wisser; Rüdiger Hehlmann; Jan Hastka
Soluble transferrin receptor and zinc protoporphyrin--competitors or efficient partners?
European journal of haematology 2005;75(4):309-17.
2005: Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Blood 2005;106(6):2162-8.
2005: Oliver Frank; Michelle Giehl; Chun Zheng; Rüdiger Hehlmann; Christine Leib-Mösch; Wolfgang Seifarth
Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorders.
Journal of virology 2005;79(17):10890-901.
2005: Alice Fabarius; Michelle Giehl; Oliver Frank; Peter Duesberg; Andreas Hochhaus; Rüdiger Hehlmann; Wolfgang Seifarth
Induction of centrosome and chromosome aberrations by imatinib in vitro.
Leukemia 2005;19(9):1573-8.
2005: Rüdiger Hehlmann; Ute Berger; Andreas Hochhaus
Chronic myeloid leukemia: a model for oncology.
Annals of hematology 2005;84(8):487-97.
2005: Georgia Metzgeroth; Andreas Reiter; Walter Back; Marco Anders; Rüdiger Hehlmann; Jan Hastka
Peritoneal haematopoiesis in acute panmyelosis with myelofibrosis.
British journal of haematology 2005;130(1):1.
2005: Michelle Giehl; Alice Fabarius; Oliver Frank; Andreas Hochhaus; M Hafner; Rüdiger Hehlmann; Wolfgang Seifarth
Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability.
Leukemia 2005;19(7):1192-7.
2005: Ute Berger; Ole Maywald; Markus Pfirrmann; Tanja Lahaye; Andreas Hochhaus; Andreas Reiter; Joerg Hasford; Hermann Heimpel; Dieter K Hossfeld; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Rüdiger Hehlmann
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Leukemia 2005;19(6):984-9.
2005: Christoph Walz; Andrew Chase; Claudia Schoch; Andreas Weisser; F Schlegel; Andreas Hochhaus; R Fuchs; A Schmitt-Gräff; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1.
Leukemia 2005;19(6):1005-9.
2005: Tanja Lahaye; Birte Riehm; Ute Berger; Peter Paschka; Martin C Müller; Sebastian Kreil; Kirsten Merx; Uwe Schwindel; Claudia Schoch; Rüdiger Hehlmann; Andreas Hochhaus
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Cancer 2005;103(8):1659-69.
2005: Lucy C Crossman; Motomi Mori; Yi-Ching Hsieh; Thoralf Lange; Peter Paschka; Christina A Harrington; Knut Krohn; Dietger Niederwieser; Rüdiger Hehlmann; Andreas Hochhaus; Brian J Druker; Michael W N Deininger
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.
Haematologica 2005;90(4):459-64.
2005: Andreas Reiter; Christoph Walz; Ann Watmore; Claudia Schoch; Ilona Blau; Brigitte Schlegelberger; Ute Berger; Nick Telford; Shilani Aruliah; John A Yin; Danny Vanstraelen; Helen F Barker; Peter C Taylor; Aisling O'Driscoll; Fabio Benedetti; Cornelia Rudolph; Hans-Jochem Kolb; Andreas Hochhaus; Rüdiger Hehlmann; Andrew Chase; Nicholas C P Cross
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
Cancer research 2005;65(7):2662-7.
2005: Senta Ulrike Gnad-Vogt; Ralf-Dieter Hofheinz; Susanne Saussele; Sebastian Kreil; Andreas Willer; Frank Willeke; Lothar Pilz; Rüdiger Hehlmann; Andreas Hochhaus
Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.
Anti-cancer drugs 2005;16(4):435-40.
2005: Joerg Hasford; Markus Pfirrmann; Pat Shepherd; Joëlle Guilhot; Rüdiger Hehlmann; François-Xavier Mahon; Hanneke C Kluin-Nelemans; Kazunori Ohnishi; Juan Luis Steegmann; Josef Thaler
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
Haematologica 2005;90(3):335-40.
2005: Ralf-Dieter Hofheinz; Bolko von Gerstenberg-Helldorf; Frederik Wenz; Ulrike Gnad; Uta Kraus-Tiefenbacher; Albrecht Müldner; Rüdiger Hehlmann; Stefan Post; Andreas Hochhaus; Frank Willeke
Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(7):1350-7.
2005: Peter Duesberg; Ruhong Li; Alice Fabarius; Rüdiger Hehlmann
The chromosomal basis of cancer.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2005;27(5-6):293-318.
2005: Jörg Bergmann; Dieter Buchheidt; Rüdiger Waldherr; Ole Maywald; Fokko J van der Woude; Rüdiger Hehlmann; Claude Braun
IgA nephropathy and hodgkin's disease: a rare coincidence. Case report and literature review.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2005;45(1):e16-9.
2005: Ralf-Dieter Hofheinz; Ulrike Gnad-Vogt; Axel Wein; Susanne Saussele; Sebastian Kreil; Lothar Pilz; Rüdiger Hehlmann; Andreas Hochhaus
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Anti-cancer drugs 2005;16(1):39-45.
2005: Wolfgang Seifarth; Oliver Frank; Udo Zeilfelder; Birgit Spiess; Alex D Greenwood; Rüdiger Hehlmann; Christine Leib-Mösch
Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray.
Journal of virology 2005;79(1):341-52.
2004: Rüdiger Hehlmann; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Nicola Gökbuget; Dieter Hoelzer; Karl Uberla
[The competence network "acute and chronic leukemias"].
Deutsche medizinische Wochenschrift (1946) 2004;129(49):2660-5.
2004: Andreas Hochhaus; Ute Berger; Rüdiger Hehlmann
[Therapy of chronic myelogenous leukemia in 2004].
Deutsche medizinische Wochenschrift (1946) 2004;129(40):2122-7.
2004: Dieter Buchheidt; Margit Hummel; Georg Engelich; Rüdiger Hehlmann
Management of infections in critically ill neutropenic cancer patients.
Journal of critical care 2004;19(3):165-73.
2004: Guntram Buesche; M Freund; Rüdiger Hehlmann; Axel Georgii; Arnold Ganser; H Hecker; Hermann Heimpel; Christa Fonatsch; Barbara Heinze; Markus Pfirrmann; S Holgado; Anita Schmeil; Andreas Tobler; Joerg Hasford; Thomas Buhr; Hans H Kreipe
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
Leukemia 2004;18(9):1460-7.
2004: Ralf-Dieter Hofheinz; Jörg Thomas Hartmann; Andreas Willer; Karin Oechsle; Gernot Hartung; Ulrike Gnad; Susanne Saussele; Sebastian Kreil; Carsten Bokemeyer; Rüdiger Hehlmann; Andreas Hochhaus
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial.
British journal of cancer 2004;91(5):834-8.
2004: Margit Hummel; Corinna Baust; Marianne Kretschmar; Thomas Nichterlein; Dietlind Schleiermacher; Birgit Spiess; Heyko Skladny; Handan Mörz; Rüdiger Hehlmann; Dieter Buchheidt
Detection of Aspergillus DNA by a nested PCR assay is superior to blood culture in an experimental murine model of invasive aspergillosis.
Journal of medical microbiology 2004;53(Pt 8):803-6.
2004: Ralf-Dieter Hofheinz; Andreas Willer; Andreas Weisser; Ulrike Gnad; Susanne Saussele; Sebastian Kreil; Jörg Thomas Hartmann; Rüdiger Hehlmann; Andreas Hochhaus
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
British journal of cancer 2004;90(10):1893-7.
2004: Dieter Buchheidt; Margit Hummel; Steffen Diehl; Rüdiger Hehlmann
Fatal cerebral involvement in systemic aspergillosis: a rare complication of steroid-treated autoimmune bicytopenia.
European journal of haematology 2004;72(5):375-6.
2004: Dieter Buchheidt; Margit Hummel; Dietlind Schleiermacher; Birgit Spiess; Rainer Schwerdtfeger; Oliver A Cornely; Stefan Wilhelm; Stefan Reuter; Winfried Kern; Thomas Südhoff; Handan Mörz; Rüdiger Hehlmann
Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients.
British journal of haematology 2004;125(2):196-202.
2004: Rüdiger Hehlmann; Ute Berger; Carlo Aul; Thomas Büchner; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Dieter Hoelzer; Nicola Gökbuget; Karl Uberla
[Clinical research in the "acute and chronic leukemias"competence network ].
Der Internist 2004;45(4):384-92.
2004: Ute Berger; Georg Engelich; Andreas Reiter; Andreas Hochhaus; Rüdiger Hehlmann
Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
Annals of hematology 2004;83(4):258-64.
2004: Dieter Buchheidt; Margit Hummel; Dietlind Schleiermacher; Birgit Spiess; Rüdiger Hehlmann
Current molecular diagnostic approaches to systemic infections with aspergillus species in patients with hematological malignancies.
Leukemia & lymphoma 2004;45(3):463-8.
2004: Ole Maywald; Dieter Buchheidt; Jörg Bergmann; Claudia Schoch; W-D Ludwig; Andreas Reiter; Jan Hastka; Eva Lengfelder; Rüdiger Hehlmann
Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection-case report and review of the literature.
Annals of hematology 2004;83(3):189-94.
2004: Ralf-Dieter Hofheinz; Xuan Duc Nguyen; Dieter Buchheidt; Mohammed Kerowgan; Rüdiger Hehlmann; Andreas Hochhaus
Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient.
Cancer chemotherapy and pharmacology 2004;53(3):276-7.
2004: Peter Duesberg; Alice Fabarius; Rüdiger Hehlmann
Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells.
IUBMB life 2004;56(2):65-81.
2004: Martin C Müller; Tanja Hördt; Peter Paschka; Kirsten Merx; Paul La Rosée; Rüdiger Hehlmann; Andreas Hochhaus
Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.
Acta haematologica 2004;112(1-2):30-3.
2004: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Carlo Aul; Eva Lengfelder; Rüdiger Hehlmann; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Hartmut Eimermacher; Norbert Frickhofen; Joachim Kienast; A Giagounidis; Maria Cristina Sauerland; Achim Heinecke
Subgroup specific therapy effects in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S100-1.
2004: Eva Lengfelder; Andreas Reiter; Susanne Saussele; Andreas Weisser; Rüdiger Hehlmann
Monitoring of minimal residual disease in acute promyelocytic leukemia.
Annals of hematology 2004;83 Suppl 1():S79-80.
2004: Ute Berger; Rüdiger Hehlmann
[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Der Internist 2004;45(1):102-3.
2003: Guntram Buesche; Rüdiger Hehlmann; H Hecker; Hermann Heimpel; Barbara Heinze; Anita Schmeil; Markus Pfirrmann; G Gomez; Andreas Tobler; H Herrmann; Martin Kappler; Joerg Hasford; Thomas Buhr; Hans H Kreipe; Axel Georgii
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
Leukemia 2003;17(12):2444-53.
2003: Martin C Müller; Norbert Gattermann; Tanja Lahaye; Michael W N Deininger; A Berndt; Stefan Fruehauf; Andreas Neubauer; Thomas Fischer; Dieter K Hossfeld; Folker Schneller; S W Krause; Christoph Nerl; Herbert G Sayer; Oliver G Ottmann; C Waller; Walter Aulitzky; Philipp le Coutre; Mathias Freund; Kirsten Merx; Peter Paschka; Heiko König; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Leukemia 2003;17(12):2392-400.
2003: M Hummel; Dieter Buchheidt; S Reiter; Jörg Bergmann; Ralf-Dieter Hofheinz; Rüdiger Hehlmann
Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.
Leukemia 2003;17(12):2542-4.
2003: Georgia Metzgeroth; Ch Sick; Ole Maywald; M Schatz; Ch Kuhn; Rüdiger Hehlmann; Jan Hastka
Multilobated nuclei in Waldenström' macroglobulinaemia.
European journal of haematology 2003;71(4):307-10.
2003: Ute Berger; Georg Engelich; Ole Maywald; Markus Pfirrmann; Andreas Hochhaus; Andreas Reiter; Georgia Metzgeroth; U Gnad; Joerg Hasford; Barbara Heinze; Hermann Heimpel; Dieter K Hossfeld; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Rüdiger Hehlmann
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Leukemia 2003;17(9):1820-6.
2003: Peter Paschka; Martin C Müller; Kirsten Merx; Sebastian Kreil; Claudia Schoch; Tanja Lahaye; Andreas Weisser; A Petzold; Heiko König; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Leukemia 2003;17(9):1687-94.
2003: Wolfgang Seifarth; Birgit Spiess; Udo Zeilfelder; Cornelia Speth; Rüdiger Hehlmann; Christine Leib-Mösch
Assessment of retroviral activity using a universal retrovirus chip.
Journal of virological methods 2003;112(1-2):79-91.
2003: Eva Lengfelder; U Gnad; T Büchner; Rüdiger Hehlmann
Treatment of relapsed acute promyelocytic leukemia.
Onkologie 2003;26(4):373-9.
2003: Rüdiger Hehlmann
Current CML therapy: progress and dilemma.
Leukemia 2003;17(6):1010-2.
2003: Tim H Brummendorf; Inci Ersoz; Ulrike Hartmann; Stefan Balabanov; Holger Wolke; Peter Paschka; Tanja Lahaye; Birgit Berner; Kerol Bartolovic; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Carsten Bokemeyer; Rüdiger Hehlmann; Klaus Dietz; Peter M Lansdorp; Lothar Kanz; Andreas Hochhaus
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Annals of the New York Academy of Sciences 2003;996():26-38.
2003: Alice Fabarius; Rüdiger Hehlmann; Peter Duesberg
Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy.
Cancer genetics and cytogenetics 2003;143(1):59-72.
2003: Birgit Spiess; Dieter Buchheidt; Corinna Baust; Heyko Skladny; Wolfgang Seifarth; Udo Zeilfelder; Christine Leib-Mösch; Handan Mörz; Rüdiger Hehlmann
Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients.
Journal of clinical microbiology 2003;41(5):1811-8.
2003: Ralf-Dieter Hofheinz; Andreas Weisser; Andreas Willer; Rüdiger Hehlmann; Andreas Hochhaus
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Onkologie 2003;26(2):161-4.
2003: Dieter Buchheidt; A Weiss; S Reiter; Gernot Hartung; Rüdiger Hehlmann
Pseudomembranous tracheobronchial aspergillosis: a rare manifestation of invasive aspergillosis in a non-neutropenic patient with Hodgkin's disease.
Mycoses 2003;46(1-2):51-5.
2003: Andreas Reiter; Susanne Saussele; David Grimwade; Joseph L Wiemels; Mark Segal; Marina Lafage-Pochitaloff; Christoph Walz; Andreas Weisser; Andreas Hochhaus; Andreas Willer; Anja Reichert; Thomas Büchner; Eva Lengfelder; Rüdiger Hehlmann; Nicholas C P Cross
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia.
Genes, chromosomes & cancer 2003;36(2):175-88.
2003: Georgia Metzgeroth; W Back; Ole Maywald; M Schatz; Andreas Willer; Rüdiger Hehlmann; Jan Hastka
Auer rod-like inclusions in multiple myeloma.
Annals of hematology 2003;82(1):57-60.
2003: Joerg Hasford; Markus Pfirrmann; Rüdiger Hehlmann; M Baccarani; françois guilhot; François-Xavier Mahon; Hanneke C Kluin-Nelemans; K Ohnishi; J Thaler; Juan Luis Steegmann
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.
Seminars in hematology 2003;40(1):4-12.
2003: Tim H Brümmendorf; Inci Ersöz; Ulrike Hartmann; Kerol Bartolovic; Stefan Balabanov; Alexandra Wahl; Peter Paschka; Sebastian Kreil; Tanja Lahaye; Ute Berger; Harald Gschaidmeier; Carsten Bokemeyer; Rüdiger Hehlmann; Klaus Dietz; Peter M Lansdorp; Lothar Kanz; Andreas Hochhaus
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Blood 2003;101(1):375-6.
2003: Andreas Burchert; Stefan Wölfl; Manuel Schmidt; Cornelia Brendel; Barbara Denecke; Dali Cai; Larissa Odyvanova; Tanja Lahaye; Martin C Müller; Thomas Berg; Harald Gschaidmeier; Burghardt Wittig; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Neubauer
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Blood 2003;101(1):259-64.
2002: Martin C Müller; Kirsten Merx; Andreas Weisser; Sebastian Kreil; Tanja Lahaye; Rüdiger Hehlmann; Andreas Hochhaus
Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization.
Leukemia 2002;16(12):2395-9.
2002: Ole Maywald; Georgia Metzgeroth; Claudia Schoch; Wolf Dieter Ludwig; Wolfgang Neff; Rüdiger Hehlmann; Jan Hastka
Alveolar rhabdomyosarcoma with bone marrow infiltration mimicking haematological neoplasia.
British journal of haematology 2002;119(3):583.
2002: Ralf-Dieter Hofheinz; Gernot Hartung; Stephan Samel; Michael Emig; Lothar Pilz; Frank Willeke; Andreas Hochhaus; Rüdiger Hehlmann; Wolfgang Queisser
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Anti-cancer drugs 2002;13(10):999-1004.
2002: Andreas Hochhaus; Sebastian Kreil; Amie S Corbin; Paul La Rosée; Martin C Müller; Tanja Lahaye; B Hanfstein; Claudia Schoch; Nicholas C P Cross; Ute Berger; Harald Gschaidmeier; Brian J Druker; Rüdiger Hehlmann
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Leukemia 2002;16(11):2190-6.
2002: Andreas Hochhaus; Ute Berger; Andreas Reiter; Georg Engelich; Tanja Lahaye; Sebastian Kreil; Kirsten Merx; Martin C Müller; Rüdiger Hehlmann
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
Der Internist 2002;43(10):1228, 1231-8, 1241-4.
2002: Kirsten Merx; Martin C Müller; Sebastian Kreil; Tanja Lahaye; Peter Paschka; Claudia Schoch; Andreas Weisser; C Kuhn; Ute Berger; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Leukemia 2002;16(9):1579-83.
2002: Thomas Fischer; C Reifenrath; G R Hess; Maria T Corsetti; Sebastian Kreil; J Beck; P Meinhardt; Germana Beltrami; B Schuch; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus; A Carella; Christoph Huber
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
Leukemia 2002;16(7):1220-8.
2002: Ralf-Dieter Hofheinz; Gernot Hartung; Stephan Samel; Andreas Hochhaus; U Pichlmeier; Stefan Post; Rüdiger Hehlmann; Wolfgang Queisser
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Onkologie 2002;25(3):255-60.
2002: Alice Fabarius; Andreas Willer; George Yerganian; Rüdiger Hehlmann; Peter Duesberg
Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(10):6778-83.
2002: Dieter Buchheidt; Corinna Baust; Heyko Skladny; Michael Baldus; Susanne Bräuninger; Rüdiger Hehlmann
Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients.
British journal of haematology 2002;116(4):803-11.
2002: Andreas Hochhaus; Ute Berger; Andreas Reiter; Rüdiger Hehlmann
[Current pharmacotherapy of chronic myeloid leukemia].
Der Internist 2002;43(2):270-83.
2002: Andreas Hochhaus; Ute Berger; Andreas Reiter; Tanja Lahaye; Sebastian Kreil; Rüdiger Hehlmann
[Drug therapy of chronic myeloid leukemia].
Medizinische Klinik (Munich, Germany : 1983) 2002;97 Suppl 1():7-15.
2001: Dieter Buchheidt; Birgit Spiess; Rüdiger Hehlmann
Systemic infections with Aspergillus species in patients with hematological malignancies: current serological and molecular diagnostic approaches.
Onkologie 2001;24(6):531-6.
2001: Francesca Bonifazi; Antonio de Vivo; Gianantonio Rosti; françois guilhot; Joëlle Guilhot; Elena Trabacchi; Rüdiger Hehlmann; A Hochhaus; P C Shepherd; Juan Luis Steegmann; Hanneke C Kluin-Nelemans; J Thaler; B Simonsson; A Louwagie; J Reiffers; François-Xavier Mahon; Enrico Montefusco; Giuliana Alimena; Joerg Hasford; S Richards; Giuseppe Saglio; Nicoletta Testoni; giovanni martinelli; Sante Tura; Michele Baccarani
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
Blood 2001;98(10):3074-81.
2001: J de la Fuente; Kirsten Merx; E J Steer; M Müller; R M Szydlo; Ole Maywald; Ute Berger; Rüdiger Hehlmann; J M Goldman; N C Cross; J V Melo; Andreas Hochhaus
ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia.
Blood 2001;98(9):2879-80.
2001: Gernot Hartung; Ralf-Dieter Hofheinz; Axel Wein; C Riedel; A Rost; D Fritze; ED Kreuser; M Drees; J Kühnel; Rüdiger Hehlmann; Wolfgang Queisser
Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer.
Onkologie 2001;24(5):457-62.
2001: Eva Lengfelder; Rüdiger Hehlmann; T Büchner
[Current therapeutic concept of acute promyelocytic leukemia].
Deutsche medizinische Wochenschrift (1946) 2001;126(39):1073-9.
2001: Peter Duesberg; R Stindl; Rüdiger Hehlmann
Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(20):11283-8.
2001: Andreas Hochhaus; Sebastian Kreil; Amie S Corbin; Paul La Rosée; Tanja Lahaye; Ute Berger; Nicholas C P Cross; W Linkesch; Brian J Druker; Rüdiger Hehlmann; C Gambacorti- Passerini; G Corneo; M D'Incalci
Roots of clinical resistance to STI-571 cancer therapy.
Science (New York, N.Y.) 2001;293(5538):2163.
2001: Andreas Hochhaus; Tanja Lahaye; Sebastian Kreil; Ute Berger; Georgia Metzgeroth; Rüdiger Hehlmann
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology].
Onkologie 2001;24 Suppl 5():65-71.
2001: Dieter Buchheidt; Corinna Baust; Heyko Skladny; J Ritter; T Suedhoff; M Baldus; Wolfgang Seifarth; C Leib-Moesch; Rüdiger Hehlmann
Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(4):428-35.
2001: Rüdiger Hehlmann
[Significance of networking for clinical research in the future].
Onkologie 2001;24(4):380-4.
2001: Andreas Reiter; Andreas Hochhaus; Ute Berger; C Kuhn; Rüdiger Hehlmann
AraC-based pharmacotherapy of chronic myeloid leukaemia.
Expert opinion on pharmacotherapy 2001;2(7):1129-35.
2001: Manuel Schmidt; Andreas Hochhaus; Andreas Nitsche; Rüdiger Hehlmann; Andreas Neubauer
Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.
Blood 2001;97(11):3648-50.
2001: Corinna Baust; Wolfgang Seifarth; Ulrike Schön; Rüdiger Hehlmann; Christine Leib-Mösch
Functional activity of HERV-K-T47D-related long terminal repeats.
Virology 2001;283(2):262-72.
2001: C Sick; B Schultheis; G Pasternak; I Kottke; S Hörner; B Heissig; Rüdiger Hehlmann
Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
Annals of hematology 2001;80(1):9-16.
2000: Peter Duesberg; R Stindl; Rüdiger Hehlmann
Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(26):14295-300.
2000: Susanne Saussele; Andreas Weisser; Martin C Müller; M Emgi; Paul La Rosée; Peter Paschka; C Kuhn; Andreas Willer; Rüdiger Hehlmann; Andreas Hochhaus
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Leukemia 2000;14(11):2006-10.
2000: Eva Lengfelder; Rüdiger Hehlmann
[Polycythemia vera: current status of therapy].
Deutsche medizinische Wochenschrift (1946) 2000;125(41):1243-7.
2000: Manuel Schmidt; Andreas Hochhaus; Sven A König-Merediz; Cornelia Brendel; J Proba; G J Hoppe; Burghardt Wittig; G Ehninger; Rüdiger Hehlmann; Andreas Neubauer
Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(19):3331-8.
2000: Rüdiger Hehlmann
Trial of IFN or STI571 before proceeding to allografting for CML?
Leukemia 2000;14(9):1560-2.
2000: Eva Lengfelder; Anja Reichert; Claudia Schoch; Detlef Haase; Torsten Haferlach; Helmut Löffler; Peter Staib; Axel Heyll; Wolfgang Seifarth; Susanne Saussele; Christa Fonatsch; Winfried Gassmann; Wolf-Dieter Ludwig; Andreas Hochhaus; D Beelen; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Rüdiger Hehlmann; Bernhard Wörmann; Wolfgang Hiddemann; Thomas Büchner
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia 2000;14(8):1362-70.
2000: Peter Duesberg; Ruhong Li; David Rasnick; C Rausch; Andreas Willer; A Kraemer; George Yerganian; Rüdiger Hehlmann
Aneuploidy precedes and segregates with chemical carcinogenesis.
Cancer genetics and cytogenetics 2000;119(2):83-93.
2000: Andreas Hochhaus; Andreas Weisser; Paul La Rosée; Michael Emig; Martin C Müller; Susanne Saussele; Andreas Reiter; C Kuhn; Ute Berger; Rüdiger Hehlmann; Nicholas C P Cross
Detection and quantification of residual disease in chronic myelogenous leukemia.
Leukemia 2000;14(6):998-1005.
2000: Wolfgang Seifarth; Ulf Krause; Christine Hohenadl; Corinna Baust; Rüdiger Hehlmann; Christine Leib-Mösch
Rapid identification of all known retroviral reverse transcriptase sequences with a novel versatile detection assay.
AIDS research and human retroviruses 2000;16(8):721-9.
2000: Corinna Baust; Wolfgang Seifarth; H Germaier; Rüdiger Hehlmann; Christine Leib-Mösch
HERV-K-T47D-Related long terminal repeats mediate polyadenylation of cellular transcripts.
Genomics 2000;66(1):98-103.
2000: Dieter Buchheidt; Heyko Skladny; Corinna Baust; Rüdiger Hehlmann
Systemic infections with Candida sp. and Aspergillus sp. in immunocompromised patients with hematological malignancies: current serological and molecular diagnostic methods.
Chemotherapy 2000;46(3):219-28.
2000: Wolfgang Seifarth; Corinna Baust; Ulrike Schön; Anja Reichert; Rüdiger Hehlmann; Christine Leib-Mösch
HERV-IP-T47D, a novel type C-related human endogenous retroviral sequence derived from T47D particles.
AIDS research and human retroviruses 2000;16(5):471-80.
2000: Eva Lengfelder; Ute Berger; Rüdiger Hehlmann
Interferon alpha in the treatment of polycythemia vera.
Annals of hematology 2000;79(3):103-9.
2000: B Heissig; G Pasternak; S Hörner; R Schwerdtfeger; S Rossol; Rüdiger Hehlmann
CD14+ peripheral blood mononuclear cells from chronic myeloid leukemia and normal donors are inhibitory to short- and long-term cultured colony-forming cells.
Leukemia research 2000;24(3):217-31.
2000: B Schultheis; G Pasternak; Rüdiger Hehlmann
BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
Folia biologica 2000;46(6):256-63.
2000: B Schultheis; B Heissig; G Pasternak; S Hörner; Rüdiger Hehlmann
Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
Folia biologica 2000;46(6):251-5.
2000: Dieter Buchheidt; Heyko Skladny; Corinna Baust; Rüdiger Hehlmann
Current serological and molecular methods in the diagnosis of systemic infections with Candida sp. and Aspergillus sp. in immunocompromised patients with hematological malignancies.
Antibiotics and chemotherapy 2000;50():59-68.
2000: Andreas Hochhaus; Andreas Reiter; Susanne Saussele; Anja Reichert; Michael Emig; J Kaeda; Beate Schultheis; Ute Berger; P C Shepherd; N C Allan; Rüdiger Hehlmann; J M Goldman; Nicholas C P Cross
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
Blood 2000;95(1):62-6.
1999: Rüdiger Hehlmann; Andreas Hochhaus; Hans-Jochem Kolb; Joerg Hasford; Alois Gratwohl; Hermann Heimpel; Wolfgang Siegert; J Finke; Gerhard Ehninger; E Holler; Ute Berger; Markus Pfirrmann; A Muth; Axel Zander; A A Fauser; A Heyll; Christoph Nerl; Dieter K Hossfeld; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Tobler
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
Blood 1999;94(11):3668-77.
1999: Heyko Skladny; Dieter Buchheidt; Corinna Baust; F Krieg-Schneider; Wolfgang Seifarth; Christine Leib-Mösch; Rüdiger Hehlmann
Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR.
Journal of clinical microbiology 1999;37(12):3865-71.
1999: Peter Duesberg; David Rasnick; Ruhong Li; L Winters; C Rausch; Rüdiger Hehlmann
How aneuploidy may cause cancer and genetic instability.
Anticancer research 1999;19(6A):4887-906.
1999: Michael Emig; Susanne Saussele; H Wittor; Andreas Weisser; Andreas Reiter; Andreas Willer; Ute Berger; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Hochhaus
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
Leukemia 1999;13(11):1825-32.
1999: G Käfer; Andreas Willer; W Ludwig; A Krämer; Rüdiger Hehlmann; Jan Hastka
Intracellular expression of CD61 precedes surface expression.
Annals of hematology 1999;78(10):472-4.
1999: Christine Hohenadl; H Germaier; Monika Walchner; M Hagenhofer; Martin Herrmann; Michael Stürzl; P Kind; Rüdiger Hehlmann; Volker Erfle; Christine Leib-Mösch
Transcriptional activation of endogenous retroviral sequences in human epidermal keratinocytes by UVB irradiation.
The Journal of investigative dermatology 1999;113(4):587-94.
1999: A Reither; Rüdiger Hehlmann; J M Goldman; N C Cross
[The 8p11 myeloproliferative syndrome].
Medizinische Klinik (Munich, Germany : 1983) 1999;94(4):207-10.
1999: Wolfgang Seifarth; F Krieg-Schneider; Heyko Skladny; A Marachelian; H Germaier; Rüdiger Hehlmann; Christine Leib-Mösch
Impact of human endogenous retroviral elements on cellular genes: strategy for isolation of LTR-driven chimeric transcripts.
Leukemia 1999;13 Suppl 1():S97-8.
1999: G Pasternak; B Schultheis; B Heissig; S Hörner; C Sick; Rüdiger Hehlmann
Does long-term culture favor normal clonogenic cells from interferon-treated patients with chronic myelogenous leukemia?
Leukemia 1999;13 Suppl 1():S55-64.
1999: A Krämer; S Hörner; A Willer; S Fruehauf; Andreas Hochhaus; M Hallek; Rüdiger Hehlmann
Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(5):2087-92.
1998: Peter Duesberg; C Rausch; David Rasnick; Rüdiger Hehlmann
Genetic instability of cancer cells is proportional to their degree of aneuploidy.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(23):13692-7.
1998: Wolfgang Seifarth; Corinna Baust; A Murr; Heyko Skladny; F Krieg-Schneider; JH Blusch; Thomas Werner; Rüdiger Hehlmann; Christine Leib-Mösch
Proviral structure, chromosomal location, and expression of HERV-K-T47D, a novel human endogenous retrovirus derived from T47D particles.
Journal of virology 1998;72(10):8384-91.
1998: Joerg Hasford; Markus Pfirrmann; Rüdiger Hehlmann; N C Allan; M Baccarani; J C Kluin-Nelemans; Giuliana Alimena; Juan Luis Steegmann; H Ansari
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
Journal of the National Cancer Institute 1998;90(11):850-8.
1998: A Krämer; Andreas Hochhaus; Susanne Saussele; Anja Reichert; Andreas Willer; Rüdiger Hehlmann
Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation.
Leukemia 1998;12(6):893-8.
1998: Thomas Fischer; A Neubauer; J Mohm; Dieter Huhn; C Busemann; H Link; Lubomir Arseniev; B Büssing; J Novotny; Arnold Ganser; Justus Duyster; D Bunjes; Sebastian Kreiter; Walter Aulitzky; Rüdiger Hehlmann; Christoph Huber
Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML.
Bone marrow transplantation 1998;21(10):1029-36.
1998: Andreas Hochhaus; Ute Berger; A Krämer; Andreas Reiter; Wolfgang Seifarth; Andreas Willer; Rüdiger Hehlmann
Congress Report: XIX symposium of the International Association for Comparative Research on Leukemia and Related Diseases, Mannheim/Heidelberg, Germany, July 13 - 18, 1997.
European journal of medical research 1998;3(4):216-22.
1998: G Pasternak; Andreas Hochhaus; B Schultheis; Rüdiger Hehlmann
Chronic myelogenous leukemia: molecular and cellular aspects.
Journal of cancer research and clinical oncology 1998;124(12):643-60.
1998: Andreas Hochhaus; Ute Berger; A Krämer; Andreas Reiter; Wolfgang Seifarth; Andreas Willer; Rüdiger Hehlmann
XIX Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, July 13-18 Mannheim/Heidelberg, Germany, 1997.
Journal of cancer research and clinical oncology 1998;124(3-4):220-30.
1998: Eva Lengfelder; Andreas Hochhaus; U Kronawitter; D Höche; Wolfgang Queisser; M Jahn-Eder; R Burkhardt; Andreas Reiter; H Ansari; Rüdiger Hehlmann
Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages.
British journal of haematology 1998;100(1):15-23.
1998: Andreas Hochhaus; Andreas Reiter; H Skladny; Anja Reichert; Susanne Saussele; Rüdiger Hehlmann
Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;144():36-45.
1997: Ruhong Li; George Yerganian; Peter Duesberg; A Kraemer; Andreas Willer; C Rausch; Rüdiger Hehlmann
Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(26):14506-11.
1997: Rüdiger Hehlmann; M Essex
Comparative research on leukemia and related diseases: an introduction to a scientific approach.
Journal of molecular medicine (Berlin, Germany) 1997;75(7):528-38.
1997: S Hörner; G Pasternak; Rüdiger Hehlmann
A statistically significant sex difference in the number of colony-forming cells from human peripheral blood.
Annals of hematology 1997;74(6):259-63.
1997: Andreas Hochhaus; F Lin; Andreas Reiter; H Skladny; Rüdiger Hehlmann; J M Goldman; N C Cross
Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
Leukemia 1997;11 Suppl 3():541-4.
1997: Rüdiger Hehlmann; Andreas Willer; Hermann Heimpel; Joerg Hasford; Hans-Jochem Kolb; Hans Pralle; Dieter K Hossfeld; Wolfgang Queisser; Helmut Löffler; Andreas Hochhaus; Andreas Tobler; Eva Lengfelder; Ute Berger; Christine Leib-Mösch
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group.
Leukemia 1997;11 Suppl 3():506-11.
1997: Andreas Reiter; Heyko Skladny; Andreas Hochhaus; Wolfgang Seifarth; H Heimpel; C R Bartram; N C Cross; Rüdiger Hehlmann
Molecular response of CML patients treated with interferon-alpha monitored by quantitative Southern blot analysis. German chronic myeloid leukaemia (CML) Study Group.
British journal of haematology 1997;97(1):86-93.
1997: Rüdiger Hehlmann; H Ansari; Joerg Hasford; Hermann Heimpel; Dieter K Hossfeld; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Reiter; Andreas Hochhaus
Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
British journal of haematology 1997;97(1):76-85.
1997: Andreas Willer; Susanne Saussele; W Gimbel; Wolfgang Seifarth; P Kister; Christine Leib-Mösch; Rüdiger Hehlmann
Two groups of endogenous MMTV related retroviral env transcripts expressed in human tissues.
Virus genes 1997;15(2):123-33.
1996: Andreas Hochhaus; Rüdiger Hehlmann
[Chronic myeloid leukemia. Current strategies in diagnosis, therapy and follow-up].
Der Internist 1996;37(10):1013-21.
1996: Andreas Hochhaus; A Reiter; Heyko Skladny; Junia V Melo; C Sick; Ute Berger; J Q Guo; R B Arlinghaus; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
Blood 1996;88(6):2236-40.
1996: Rüdiger Hehlmann; Hermann Heimpel
Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival.
Leukemia & lymphoma 1996;22 Suppl 1():161-7.
1996: E Lengfelder; M Griesshammer; Rüdiger Hehlmann
Interferon-alpha in the treatment of essential thrombocythemia.
Leukemia & lymphoma 1996;22 Suppl 1():135-42.
1996: E Lengfelder; Rüdiger Hehlmann
Intensive combination chemotherapy in treatment of CML.
Bone marrow transplantation 1996;17 Suppl 3():S55-7.
1996: Joerg Hasford; H Ansari; Markus Pfirrmann; Rüdiger Hehlmann
Analysis and validation of prognostic factors for CML. German CML Study Group.
Bone marrow transplantation 1996;17 Suppl 3():S49-54.
1996: Andreas Hochhaus; F Lin; A Reiter; Heyko Skladny; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.
Bone marrow transplantation 1996;17 Suppl 3():S41-4.
1996: Hermann Heimpel; N C Allan; M Baccarani; françois guilhot; Rüdiger Hehlmann; M Horowitz; J Kluin-Nelemans; U Schaefer; R Storb; J Thaler
Current controversies on the role of interferon-alpha for therapy of chronic myeloid leukemia.
Bone marrow transplantation 1996;17 Suppl 3():S39.
1996: Rüdiger Hehlmann; Hermann Heimpel; Dieter K Hossfeld; Joerg Hasford; Hans-Jochem Kolb; Helmut Löffler; Hans Pralle; Wolfgang Queisser; Andreas Hochhaus; A Tichelli; W Fett; Norbert Schmitz; A Reiter; Martin Griesshammer; W Pfeifer; M Bümler; T Kamp; Andreas Tobler; Hartmut Eimermacher; R Kuse; Ute Berger; H Ansari
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
Bone marrow transplantation 1996;17 Suppl 3():S21-4.
1996: J Hastka; J J Lasserre; A Schwarzbeck; A Reiter; Rüdiger Hehlmann
Laboratory tests of iron status: correlation or common sense?
Clinical chemistry 1996;42(5):718-24.
1996: M Schenk; Christine Leib-Mösch; I U Schenck; M Jaenicke; Stefano Indraccolo; H D Saeger; G Dallenbach-Hellweg; Rüdiger Hehlmann
Lower frequency of allele loss on chromosome 18q in human breast cancer than in colorectal tumors.
Journal of molecular medicine (Berlin, Germany) 1996;74(3):155-9.
1996: Andreas Hochhaus; F Lin; A Reiter; Heyko Skladny; Philip J Mason; F van Rhee; P C Shepherd; N C Allan; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
Blood 1996;87(4):1549-55.
1996: Rüdiger Hehlmann
[Chronic myeloid leukemia].
Therapeutische Umschau. Revue thérapeutique 1996;53(2):82-7.
1996: Christine Hohenadl; Christine Leib-Mösch; Rüdiger Hehlmann; V Erfle
Biological significance of human endogenous retroviral sequences.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;13 Suppl 1():S268-73.
1995: Wolfgang Seifarth; Heyko Skladny; F Krieg-Schneider; A Reichert; Rüdiger Hehlmann; Christine Leib-Mösch
Retrovirus-like particles released from the human breast cancer cell line T47-D display type B- and C-related endogenous retroviral sequences.
Journal of virology 1995;69(10):6408-16.
1995: Andreas Hochhaus; F Lin; A Reiter; Heyko Skladny; F van Rhee; P C Shepherd; N C Allan; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
British journal of haematology 1995;91(1):126-31.
1995: M Haltmeier; Wolfgang Seifarth; J Blusch; V Erfle; Rüdiger Hehlmann; Christine Leib-Mösch
Identification of S71-related human endogenous retroviral sequences with full-length pol genes.
Virology 1995;209(2):550-60.
1994: Rüdiger Hehlmann; Hermann Heimpel; Joerg Hasford; Hans-Jochem Kolb; Hans Pralle; Dieter K Hossfeld; Wolfgang Queisser; Helmut Löffler; Andreas Hochhaus; Barbara Heinze
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Blood 1994;84(12):4064-77.
1994: P Von Wussow; Rüdiger Hehlmann; T Hochhaus; D Jakschies; K U Nolte; O Prümmer; H Ansari; Joerg Hasford; H Heimpel; HR Deicher
Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia.
Journal of interferon research 1994;14(4):217-9.
1994: J Hastka; J J Lasserre; A Schwarzbeck; Rüdiger Hehlmann
Central role of zinc protoporphyrin in staging iron deficiency.
Clinical chemistry 1994;40(5):768-73.
1994: Rüdiger Hehlmann; P Kister; Andreas Willer; M Simon; M Schenk; Wolfgang Seifarth; G Papakonstantinou; Susanne Saussele; Hans-Jochem Kolb; H Ansari
Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
Leukemia 1994;8 Suppl 1():S127-32.
1994: M Simon; M Haltmeier; G Papakonstantinou; Thomas Werner; Rüdiger Hehlmann; Christine Leib-Mösch
Transcription of HERV-K-related LTRs in human placenta and leukemic cells.
Leukemia 1994;8 Suppl 1():S12-7.
1994: Rüdiger Hehlmann
[Chronic myeloid leukemia. State of the art, May 1993].
Schweizerische medizinische Wochenschrift 1994;124(1-2):37-43.
1994: Rüdiger Hehlmann; H Ansari; V Adelberger; Barbara Heinze; K Hossfeld; Andreas Hochhaus; Hermann Heimpel
New perspectives with interferon alpha. The German CML study group experience.
Bone marrow transplantation 1994;14 Suppl 3():S14-20.
1993: Christine Leib-Mösch; M Haltmeier; Thomas Werner; E M Geigl; Ruth Brack-Werner; U Francke; V Erfle; Rüdiger Hehlmann
Genomic distribution and transcription of solitary HERV-K LTRs.
Genomics 1993;18(2):261-9.
1993: Martin Griesshammer; Rüdiger Hehlmann; Andreas Hochhaus; Moshe Talpaz; S Tura; P Stryckmans; N C Allan; J Tanzer; H J Kolb; Hermann Heimpel
Interferon in chronic myeloid leukemia. A workshop report.
Annals of hematology 1993;67(2):101-6.
1993: Rüdiger Hehlmann; Hermann Heimpel; Joerg Hasford; Hans-Jochem Kolb; Hans Pralle; Dieter K Hossfeld; Wolfgang Queisser; Helmut Löffler; Barbara Heinze; A Georgii
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
Blood 1993;82(2):398-407.
1993: Rüdiger Hehlmann; H Ansari; Joerg Hasford; Hermann Heimpel
Chronic myelogenous leukemia: progress in chemotherapy and evaluation of prognostic score 1. The German CML Study Group.
Seminars in hematology 1993;30(3 Suppl 3):44-8.
1993: O Faff; B A Murray; V Erfle; Rüdiger Hehlmann
Large scale production and purification of human retrovirus-like particles related to the mouse mammary tumor virus.
FEMS microbiology letters 1993;109(2-3):289-96.
1993: J Hastka; J J Lasserre; A Schwarzbeck; M Strauch; Rüdiger Hehlmann
Zinc protoporphyrin in anemia of chronic disorders.
Blood 1993;81(5):1200-4.
1993: G Papakonstantinou; J R Bogner; F Hofmeister; Rüdiger Hehlmann
Cefotaxime desensitization.
The Clinical investigator 1993;71(2):165-7.
1993: Rüdiger Hehlmann; Hermann Heimpel; Hans-Jochem Kolb; Barbara Heinze; Andreas Hochhaus; Martin Griesshammer; Hans Pralle; Wolfgang Queisser; U Essers; C Falge
The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Leukemia & lymphoma 1993;11 Suppl 1():159-68.
1992: J Hastka; J J Lasserre; A Schwarzbeck; M Strauch; Rüdiger Hehlmann
Washing erythrocytes to remove interferents in measurements of zinc protoporphyrin by front-face hematofluorometry.
Clinical chemistry 1992;38(11):2184-9.
1992: O Faff; A B Murray; J Schmidt; Christine Leib-Mösch; V Erfle; Rüdiger Hehlmann
Retrovirus-like particles from the human T47D cell line are related to mouse mammary tumour virus and are of human endogenous origin.
The Journal of general virology 1992;73 ( Pt 5)():1087-97.
1992: Christine Leib-Mösch; M Bachmann; Ruth Brack-Werner; Thomas Werner; V Erfle; Rüdiger Hehlmann
Expression and biological significance of human endogenous retroviral sequences.
Leukemia 1992;6 Suppl 3():72S-75S.
1992: Rüdiger Hehlmann; Hermann Heimpel; Martin Griesshammer; Hans-Jochem Kolb; Barbara Heinze; Dieter K Hossfeld; P D Wickramanayake; U Essers; J Thiele; A Georgii
Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group.
Leukemia 1992;6 Suppl 3():110S-114S.
1991: P V Wussow; D Jakschies; Mathias Freund; Rüdiger Hehlmann; F Brockhaus; H Hochkeppel; M Horisberger; HR Deicher
Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
British journal of haematology 1991;78(2):210-6.
1991: Rüdiger Hehlmann; H Heimpel; Barbara Heinze; A Georgii; Hans-Jochem Kolb; Dieter K Hossfeld; P von Wussow; Andreas Hochhaus; Martin Griesshammer; V Diehl
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)].
Onkologie 1991;14(1):66-73.
1990: Christine Leib-Mösch; Ruth Brack-Werner; B Salmons; J Schmidt; P G Strauss; Rüdiger Hehlmann; V Erfle
The significance of retroviruses in oncology.
Onkologie 1990;13(6):405-14.
1990: H Schetters; H Rohmer; Rüdiger Hehlmann; Volker Erfle
Quantitative determination of retrovirus-specific immune complexes.
Journal of immunological methods 1990;134(1):113-9.
1990: Christine Leib-Mösch; Ruth Brack-Werner; T Werner; M Bachmann; O Faff; V Erfle; Rüdiger Hehlmann
Endogenous retroviral elements in human DNA.
Cancer research 1990;50(17 Suppl):5636S-5642S.
1990: B Anger; Johannes W G Janssen; Hubert Schrezenmeier; Rüdiger Hehlmann; Hermann Heimpel; Claus R Bartram
Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms.
Leukemia 1990;4(4):258-61.
1989: G Papakonstantinou; H Füessl; A Matuschke; Rüdiger Hehlmann
Therapy of pneumocystis carinii pneumonia after trimethoprim-sulfamethoxazole desensitization.
Klinische Wochenschrift 1989;67(5):316.
1988: G Papakonstantinou; C Eisenhut; H Füessl; Rüdiger Hehlmann
[IgD paraproteinemia in immunocytoma].
Klinische Wochenschrift 1988;66(20):1029-33.
1988: G Papakonstantinou; H Füessl; Rüdiger Hehlmann
Trimethoprim-sulfamethoxazole desensitization in AIDS.
Klinische Wochenschrift 1988;66(8):351-3.
1988: Rüdiger Hehlmann; B Anger; D Messerer; R Zankovich; L Bergmann; H J Kolb; P Meyer; U Essers; U Queisser; H Vaupel
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.
Blut 1988;56(2):87-91.
1985: H Schetters; Rüdiger Hehlmann; Volker Erfle; G Kreeb; H Rohmer; J Schmidt
Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSV gp70: prevalence and distribution in human sera.
European journal of cancer & clinical oncology 1985;21(6):687-700.
1985: W Gössner; Rüdiger Hehlmann; M A Schreiber; K J Lohe; K Prechtel; R Mesa-Tejada
[Immunohistochemical studies with retrovirus-specific antibodies in benign and malignant diseases of the breast].
Verhandlungen der Deutschen Gesellschaft für Pathologie 1985;69():249-53.
1984: Rüdiger Hehlmann; Volker Erfle; H Schetters; A Luz; H Rohmer; M A Schreiber; H Pralle; U Essers; W Weber
Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp70. Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis.
Cancer 1984;54(12):2927-35.
1983: Rüdiger Hehlmann; H Schetters; G Kreeb; Volker Erfle; J Schmidt; A Luz
RNA-tumorviruses, oncogenes, and their possible role in human carcinogenesis.
Klinische Wochenschrift 1983;61(24):1217-31.
1983: H Rohmer; H Schetters; A Luz; Rüdiger Hehlmann; Volker Erfle
Detection of antigen-(AKR MuLV gp70)-specific circulating immune complexes (CIC) in mice with lymphomas.
Haematology and blood transfusion 1983;28():493-7.
1981: Volker Erfle; Rüdiger Hehlmann; H Schetters; J Schmidt; A Luz
Radiation-induced murine leukemias and endogenous retroviruses: the time course of viral expression.
Haematology and blood transfusion 1981;26():537-40.
1981: Rüdiger Hehlmann; A Baumgarten; M A Schreiber; H Schetters; A Luz; R Mesa-Tejada; K J Lohe; K Prechtel
[Cross-reaction of human breast cancers with the envelope glycoprotein gp 52 of the mouse mamma tumorvirus (MMTV)].
Verhandlungen der Deutschen Gesellschaft für Pathologie 1981;65():275-9.